Raymond James raised the price target for the Bristol-Myers Squibb Company (NYSE:BMY) stock from ‘an Outperform’ to ‘a Mkt perform’. The rating was released on June 03, 2023, according to finviz. The research report from Goldman has initiated the stock to Buy, with a price target set at $72. The stock was resumed by Wells Fargo, who disclosed in a research note on December 09, 2021, to Equal Weight and set the price objective to $58. In their research brief published November 19, 2021, BMO Capital Markets analysts initiated the Bristol-Myers Squibb Company stock to Outperform with a price target of $72.
Skip to content
monetize bricks-and-clicks action-items
